Melflufen in Multiple Myeloma
Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload. Aminopeptidases are overexpressed in tumor cells and are even more pronounced in advanced cancers and tumors with a high mutational burden.
In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.
The melflufen molecule
Priority review by FDA
Melflufen is an investigational drug and is not approved for commercial use. The U.S. FDA has granted priority review for Oncopeptides´ New Drug Application seeking accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD-38 monoclonal antibody, i.e., triple-class refractory multiple myeloma patients.
HORIZON study basis for submission
The NDA submission is based on the results from the pivotal phase 2 HORIZON study, in which melflufen plus dexamethasone demonstrated encouraging efficacy and a clinically manageable safety profile in heavily pretreated patients with relapsed refractory multiple myeloma, primarily hematologic adverse events and a low incidence of non-hematologic adverse events.
Multiple Myeloma is classified as a rare disease in the US and in Europe, and melflufen has been granted orphan designation by the Food and Drug Administration, FDA, and the European Medicines Agency, EMA.
* National Cancer Institute, SEER Cancer Statistics Review 1975-2013 (2016) for patients in USA and GlobalData (2015).